【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]Biosolution Reports Positive U.S. Phase2 Results

온카뱅크관리자

2025-05-08 10:07:29

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
         <section dmcf-sid="GpX7c7xpE9">
          <p contents-hash="4e6953e837e5da0bfcb233ec9d2b5f69b91b3c14fb80e3ccd3f0ee620b181bed" dmcf-pid="HUZzkzMUmK" dmcf-ptype="general"> [Seok Ji-hoen, edaily reporter] Biosolution said Wednesday it has received the final clinical study report (CSR) for the Phase 2 U.S. trial of its next-generation cell therapy CartiLife, developed for knee cartilage regeneration.</p>
          <figure class="figure_frm origin_fig" contents-hash="78a24ee9fd611c1435e2a0ca98988012320724db4ce4e42f7dce9a334730c81c" dmcf-pid="Xu5qEqRuDb" dmcf-ptype="figure">
           <p class="link_figure"><img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202505/08/Edaily/20250508095923004uyez.jpg" data-org-width="502" dmcf-mid="YvasKsZwO2" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202505/08/Edaily/20250508095923004uyez.jpg" width="658"></p>
          </figure>
          <div contents-hash="704a7cc4ab270a26cc09dd5563864d1864698e66d66826cd37ff39a82a0608d8" dmcf-pid="Z71BDBe7rB" dmcf-ptype="general">
           According to the company, top-line data from the Phase 2 study demonstrated CartiLife’s ability to structurally regenerate and preserve cartilage, while also improving symptoms. Notably, about 37% of the patients had osteoarthritis, and showed statistically significant improvements in pain and joint function compared to baseline as well as evidence of cartilage regeneration.
          </div>
          <p contents-hash="1bd15fc99f13456d5e6b71647dd4b5284ff59b6f0a1106b6c608f218719e03ce" dmcf-pid="5ztbwbdzmq" dmcf-ptype="general">The U.S. Phase 2 trial began after Biosolution received FDA clearance for its IND in November 2019. The study enrolled 20 patients with cartilage defects of the knee, across five U.S. clinical sites. Dosing was completed in January 2024.</p>
          <p contents-hash="82f8c8c8702d4b7bc572e6419137d2ca85e28bfec7105a4286297cd556e8cbb2" dmcf-pid="1lwTPTUlEz" dmcf-ptype="general">The trial population included middle-aged and older adults, with an average age of 53 and a maximum age of 62. Most participants were mildly obese, with BMIs around 30. Despite having severe cartilage defects classified as ICRS grades 3~4, the patients showed positive outcomes, the company said. These findings suggest that CartiLife is effective even in real-world settings, including among older, obese, and advanced osteoarthritis patients.</p>
          <p contents-hash="32dbe9bce715a4549f4a685e7b5451704820f7759da985d7b397db6b8d036af9" dmcf-pid="tSryQyuSw7" dmcf-ptype="general">At week 48 post surgery, the primary endpoint “cartilage defect fill score” averaged 14.2 out of 20. That compares favorably with the 9 point average typically seen with microfracture surgery in Korea’s Phase 3 trials. Biosolution used both cartilage fill and functional improvement scores as co-primary endpoints, a move the company said reflects its confidence in the therapy.</p>
          <p contents-hash="34aee571c37ed7e74a63d21d07117a73a1b7db7e20d57b0cce47f4e2128a256d" dmcf-pid="FvmWxW7vIu" dmcf-ptype="general">In addition to significant improvement in the KOOS Sports/Recreation score, which rose from 16.8 at baseline to 52.5, other KOOS subdomain scores-including pain, symptoms, activities of daily living, and quality of life-also improved significantly. The overall KOOS score increased from 37.9 to 70.5. The KOOS Symptoms score, which measures swelling and stiffness, rose from 52.8 to 83.6. KOOS Pain scores also showed statistically significant improvements over time.</p>
          <p contents-hash="e0843e61f87f87f0ab04420a2518dfa91646a3984b3561e142738aa8f0c65f08" dmcf-pid="3TsYMYzTrU" dmcf-ptype="general">MRI-based assessment using the MOCART score, a key imaging endpoint for cartilage regeneration, averaged in the 80s. That’s higher than the 75.7 reported for Vericel’s MACI, a U.S.-approved cartilage cell therapy, at a scientific conference in 2010. Most similar products or devices tested in Korean trials have shown MOCART scores in the 50~60 range.</p>
          <p contents-hash="93bed2de02a9590e7c72caaa23bf8d0f1ae4143fc08eb879a89e6b13e8047cef" dmcf-pid="0yOGRGqyEp" dmcf-ptype="general">Other secondary endpoints, including VAS for pain and WOMAC for function, also demonstrated statistically significant improvement, according to the company.</p>
          <p contents-hash="e62fd9bb8e580ea57136f8d5298c487e7ea8c85ed13f733da259cc14d2d036ec" dmcf-pid="pWIHeHBWw0" dmcf-ptype="general">“With CartiLife’s efficacy now reconfirmed through both its official product approval in Korea and this U.S. Phase 2 study, we will now focus on early commercialization,” said CEO Jung-sun Lee. “We will publish detailed findings in international journals and accelerate license-out discussions for CartiLife, while also working with the FDA to advance early market entry.”</p>
          <p contents-hash="d3100b559a2464b4ad166d4a88d3848e751c1e810c0fddb855f77ab272f86178" dmcf-pid="UYCXdXbYE3" dmcf-ptype="general">석지헌 (cake@edaily.co.kr) </p>
         </section> 
        </div> 
        <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기